


N-Acyl Amino Acid Ligands for Ruthenium(II)-Catalyzed *meta*-C–H *tert*-Alkylation with Removable Auxiliaries

Jie Li, Svenja Warratz, Daniel Zell, Suman De Sarkar, Eloisa Eriko Ishikawa, and Lutz Ackermann*

Institut für Organische und Biomolekulare Chemie, Georg-August-Universität, Tammannstrasse 2, 37077 Göttingen, Germany

Supporting Information

ABSTRACT: Acylated amino acid ligands enabled ruthenium-(II)-catalyzed C-H functionalizations with excellent levels of *meta*-selectivity. The outstanding catalytic activity of the ruthenium(II) complexes derived from monoprotected amino acids (MPAA) set the stage for the first ruthenium-catalyzed *meta*-functionalizations with removable directing groups. Thereby, *meta*-alkylated anilines could be accessed, which are difficult to prepare by other means of direct aniline functionalizations. The robust nature of the versatile ruthenium(II)-MPAA was reflected by challenging remote



ruthenium(II)–MPAA was reflected by challenging remote C–H transformations with tertiary alkyl halides on aniline derivatives as well as on pyridyl-, pyrimidyl-, and pyrazolyl-substituted arenes. Detailed mechanistic studies provided strong support for an initial reversible C–H ruthenation, followed by a SET-type C–Hal activation through homolytic bond cleavage. Kinetic analyses confirmed this hypothesis through an unusual second-order dependence of the reaction rate on the ruthenium catalyst concentration. Overall, this report highlights the exceptional catalytic activity of ruthenium complexes derived from acylated amino acids, which should prove instrumental for C–H activation chemistry beyond remote functionalization.

INTRODUCTION

The direct transformation of otherwise inert C-H bonds as latent functional groups has received considerable attention, because this approach avoids the use of prefunctionalized starting materials.¹ Since the substrates of interest usually display numerous C-H bonds with close dissociation energies, controlling the positional selectivity represents the key challenge in intermolecular C-H functionalizations.^{1,2} In this context, the recent years have witnessed remarkable progress through the use of Lewis-basic entities that allowed for proximity-induced C-H transformations.³ Thus, site-selectivity ensuring entities have been identified, which set the stage for entropically favored C-H metalations by substrate precoordination to the metal catalyst.^{1,3,4} Despite significant recent advances, the vast majority of chelation-assisted C-H activations provided solely access to a plethora of orthofunctionalized products.¹ In stark contrast, general methods for meta-selective C-H functionalizations continue to be scarce.⁵ Notable exceptions include remote C-H transformations that exploit the inherent steric or electronic features of substratecatalyst interactions (Figure 1a).⁶ As an alternative, rationally designed templates were elegantly devised by, among others, Yu and co-workers (Figure 1b).⁷ To avoid a stoichiometric template, transient covalent or secondary hydrogen-bonding interactions set very recently the stage for *meta*-selective C-H functionalizations (Figure 1c), as elegantly devised by Yu⁸ and Dong.^{9,10}

In contrast, ruthenium(II) complexes¹¹ were recently shown to facilitate *meta*-selective C–H functionalizations by means of chelation-assisted cyclometalation (Figure 1d).¹² While these

reports indicated a unique strategy for remote meta-C-H activation, the approach was thus far significantly limited to strongly coordinating heteroaromatic pyridyl,^{12b-d} pyrazolyl,^{12c} imidazolyl,^{12c} or pyrimidyl^{12c} directing groups, which are unfortunately very difficult to remove¹³ or modify. Hence, ruthenium-catalyzed meta-selective C-H functionalizations with removable directing groups have as of yet unfortunately proven elusive. Another notable limitation was constituted in that ruthenium(II)-catalyzed meta-C-H functionalizations were thus far not amenable to electron-rich arenes, such as synthetically useful anilines. In consideration of the practical importance of aniline derivatives in inter alia drug discovery, crop protection, and material sciences,¹⁴ we set out to devise ruthenium catalysts for meta-selective C-H functionalizations of N-(pyrimidine-2-yl)anilines,¹⁵ important structural motifs of biologically active compounds of relevance to pharmacologically active ingredients (Figure 2).¹⁶ As a result of our efforts, we herein¹⁷ report on a novel ligand design for rutheniumcatalyzed C-H functionalizations that allowed for the challenging meta-C-H activation on electron-rich aniline derivatives. Thus, monoprotected amino acids (MPAA), employed by Yu¹⁸ for palladium-catalyzed transformations, proved to be the best in class ligands for ruthenium(II)catalyzed remote C-H functionalizations. Notable features of our C-H activation strategy are (i) an unprecedented high catalytic activity in ruthenium-catalyzed meta-C-H-activation through MPAA ligand acceleration, (ii) exceptionally high

Received: August 10, 2015 Published: September 29, 2015

(a) Steric control: Iridium, Rhodium




Figure 1. Strategies for *meta*-selective C–H functionalization. (a) Steric interactions controlling site-selectivity. (b) Template-assisted transformation. (c) Norbornene as mediator. (d) Remote σ -activation. (e) Ruthenium(II)–MPAA-catalyzed *meta*-selective alkylation with removable directing groups; pym = pyrimidyl.




Figure 2. Representative bioactive *meta*-substituted *N*-(pyrimidine-2-yl)anilines.

levels of *meta*-selectivity, (iii) remote C–H functionalizations with synthetically useful removable auxiliaries, and (iv) C–H transformations with challenging tertiary alkyl halides (Figure 1e).¹⁹ With respect to the last point, notable progress has been made in metal-catalyzed cross-coupling, including the development of nickel catalysts to promote challenging coupling reactions of unactivated tertiary alkyl halides by Fu and coworkers.²⁰

RESULTS AND DISCUSSION

Aniline Derivatives: Optimization. At the outset of our studies, we probed reaction conditions that we had previously optimized for the ruthenium(II)-catalyzed *meta*-alkylation of 2-phenylpyridines with secondary alkyl bromides.^{12c} To our delight, the desired *meta*-alkylated product was obtained in 30%

yield (Table 1, entry 1). KOAc also proved to be a competent ligand, albeit leading to a significantly lower yield (entry 2).


Table 1. Optimization of meta-Selective tert-Alkylation ^a				
H F	+ t -BuBr - K_2CO_3	at. [Ru] <i>ligand</i> , 1,4-dioxane 0 °C, 16 h		
entry	catalyst	ligand	yield (%)	
1	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	MesCO ₂ H	30	
2	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	KOAc	26	
3	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$		0	
4	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Piv-Phe-OH	50	
5	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Piv-Leu-OH	58	
6	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Piv-Val-OH	66	
7	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	H-Val-OH	18	
8	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Boc ₂ -Val-OH	54	
9	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	MeO ₂ C-Val-OH	58	
10	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Boc-Val-OH	55	
11	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Ac-Val-OH	47	
12	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	1-Ad-Val-OH	62	
13	$[\operatorname{RuCl}_2(p\operatorname{-cymene})]_2$	1-Ad-Ile-OH	65	
14	[RuCl(Piv-Val-O)(p-cymene)]	(4)	56	
^{<i>a</i>} Reaction conditions: 1a (0.5 mmol), 2a (1.5 mmol), $[RuCl_2(p-1)]$				

cymene)]₂ (5.0 mol %), ligand (30 mol %), K₂CO₃ (1.0 mmol), 1,4dioxane (2 mL), 100 °C, 16 h; yields of isolated products.

While the reaction did not occur in the absence of an additive (entry 3), a considerably improved catalytic efficacy proved viable with the MPAA Piv-Phe-OH as the ligand (entry 4). While ruthenium(II)-amino acid complexes are well established in the literature,²¹ MPAAs have as of yet not been exploited for ruthenium-catalyzed C-H functionalizations. Encouraged by our initial lead, we examined differently substituted MPAA ligands. Thus, among a representative set of pivaloyl-protected amino acids, the valine derivative turned out to be optimal (entries 4-6). In contrast, the parent amino acid valine delivered the desired arene 3aa only in an unsatisfactorily low yield, highlighting the importance of the amide moiety and its N-substitution pattern (entry 7). In agreement with this observation, N,N-disubstituted valine bearing the amide motif proved to be a competent ligand (entry 8). Further N-protected MPAAs afforded the metaalkylated product 3aa in comparable yields (entries 9-13). To unravel the nature of the in situ generated ruthenium catalyst, we independently prepared the ruthenium(II)-MPAA complex 4. Intriguingly, the single-component ruthenium(II) species 4 was found to be catalytically active, despite the decreased ligand loading (entry 14).


Thereafter, we explored the dependence of the ruthenium-(II)-catalyzed *meta*-C–H alkylation on the nature of the aniline's *N*-substitution pattern (Scheme 1). Interestingly, the switch from the pyrimidyl to the more strongly coordinating²² pyridyl group resulted in a considerable loss in catalytic efficacy.


Scheme 1. Effect of the N-Substitution Pattern



Moreover, a simple diarylaniline failed to furnish the desired product, thereby highlighting the relevance of chelation assistance.

Scope and Limitations. With the optimized ruthenium(II) catalytic system in hand, we explored its scope and limitations in the *meta*-selective *tert*-alkylation (Scheme 2). We were






^{*a*}(a) Reaction conditions: **1** (0.5 mmol), **2** (1.5 mmol), $[RuCl_2(p-cymene)]_2$ (5.0 mol %), Piv-Val-OH (30 mol %), K₂CO₃ (1.0 mmol), 1,4-dioxane (2.0 mL), 16 h, 120 °C; yields of isolated products. (b) 1-Ad-Ile-OH (30 mol %).


pleased to observe that the ruthenium-MPAA complex was broadly applicable. Thus, electron-rich as well as functionalized arenes 1 bearing bromo or chloro substituents were efficiently converted, furnishing the desired meta-alkylated products 3ba-3ea. Notably, the ligand Ad-Ile-OH even enabled the direct meta-alkylation of challenging ortho-substituted substrates, furnishing the tert-alkylated products 3fa and 3ga through the exclusive functionalization at the sterically more congested meta-C-H bond. The 2,4-disubstituted aniline 1h was smoothly alkylated at the 3-position within an intramolecular competition, illustrating the excellent site-selectivity of the approach. Subsequently, we tested a variety of tertiary alkyl bromides 2 in the C-H transformation. Thus, cyclic tertiary bromide 2b delivered the desired product 3ab in 60% yield. Likewise, sterically more hindered acyclic tertiary alkyl bromides 2 also afforded the corresponding products. Aryland alkenyl-substituted alkyl bromides 2e and 2f were well tolerated, thereby providing a handle for further postsynthetic diversifications. It should be noted that the alkyl bromide 2g displaying a primary alkyl chloride was chemo-selectively converted at the more hindered site on the alkyl halide (3ag). This observation clearly unraveled the relative reactivity pattern within the ruthenium(II)-catalyzed C-H alkylation process (vide infra).

Intriguingly, the pyrimidyl group could be reliably cleaved in a traceless fashion, providing *meta*-alkylated aniline derivative **7aa** in 84% yield (Scheme 3). Thereby, our strategy offers a novel approach for the step-economical synthesis of *meta*substituted anilines 7, which are extremely difficult to access by other aniline functionalization methods.





Heteroarenes: Optimization. Given the unique catalytic efficacy of the ruthenium–MPAA complex in the C–H functionalization with aniline derivatives **3**, we became attracted by exploring its versatility with differently decorated arenes. Hence, we tested various in situ generated ruthenium(II) catalysts in the direct functionalization of pyridyl-substituted²³ arene **8a** (Table 2). The desired reaction could not be achieved




	H MeO 8a 2a H H H H H H H H H H H H H H H H H	bxane t-Bu	N N
entry	catalyst	ligand	yield (%)
1	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$		0
2	$[RuCl_2(p-cymene)]_2$	KOAc	50
3	$[RuCl_2(p-cymene)]_2$	Piv-Leu-OH	55
4	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Piv-Gly-OH	48
5	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Piv-Phe-OH	53
6	[RuCl ₂ (<i>p</i> -cymene)] ₂	Piv-Val-OH	76
7	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	H-Val-OH	19
8	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Boc ₂ -Val-OH	46
9	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	MeO ₂ C-Val-OH	58
10	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Boc-Val-OH	61
11	$[\operatorname{RuCl}_2(p\text{-cymene})]_2$	Ad-Val-OH	55
12	[RuCl(Piv-Val-O)(p-cymene)] (4)		80
13		Piv-Val-OH	0

"Reaction conditions: 8a (0.5 mmol), 2a (1.5 mmol), $[RuCl_2(p-cymene)]_2$ (5.0 mol %), ligand (30 mol %), K_2CO_3 (1.0 mmol), 1,4-dioxane (2 mL), 100 °C, 20 h, under N_2 ; yields of isolated products.

solely with $[RuCl_2(p\text{-cymene})]_2$ in the absence of any ligand (entry 1). Likewise, the ligand KOAc furnished only an unsatisfactorily low yield (entry 2), while Frost observed in very recent independent studies high conversions with KOAc as the stoichiometric base at an elevated reaction temperature of 120 °C.^{12d} Among a set of representative amino acid derivatives, Piv-Val-OH was again found to be the ligand of choice (entries 3–11). It is noteworthy that the single-component ruthenium-(II)–MPAA complex 4 delivered the product 9aa in an improved yield of 80% at a significantly reduced ligand loading (entry 12). Finally, a control experiment confirmed that the ruthenium catalyst proved to be essential (entry 13).

Scope and Limitations. After having optimized the reaction conditions, we explored the generality of both the in situ formed ruthenium(II) catalytic system (Scheme 4, conditions A) as well as the single-component complex 4 (conditions B). Generally, the in situ formed and the well-defined ruthenium(II)-MPAA catalysts 4 furnished comparable results. Thus, the parent unsubstituted 2-phenylpyridine (8b) as well as the *para*-substituted derivatives 8a and 8c were efficiently converted under both reaction conditions (9aa–9ca). Phenylpyridines 8c-8e bearing electron-withdrawing fluoro, acetyl, or ester groups in the *para*-position selectively delivered the corresponding *meta*-alkylated products. It is

Scheme 4. Scope of Heteroarene-Assisted meta-C-H tert-Alkylation^a





^{*a*}(a) Reaction conditions: (A) $[RuCl_2(p\text{-cymene})]_2$ (2.5 mol %), Piv-Val-OH (30 mol %) or (B) [RuCl(Piv-Val-O)(p-cymene)] (5.0 mol %); 8 (0.5 mmol), 2 (1.5 mmol), K₂CO₃ (1.0 mmol), 1,4-dioxane (2.0 mL), 20 h, 100 °C under N₂ atm; yields of isolated products. (b) $[RuCl_2(p\text{-cymene})]_2$ (5.0 mol %) or [RuCl(Piv-Val-O)(p-cymene)] (4, 10 mol %).


noteworthy that C-H functionalizations of substrates 8a-8e at the ortho-position of a weakly coordinating directing ether, halo, ketone, or ester in the presence of a strongly coordinating pyridine substituent are extremely difficult to achieve. Different substituents in the 3, 4, or 5 position on the pyridine moiety were well tolerated by the ruthenium(II) catalyst (9fa-9ka), with electron-donating substituents slightly improving the performance. Given the importance of heteroarenes as key motifs in various bioactive compounds,²⁴ we were delighted to observe that the remote C-H tert-alkylation of substituted thiophene 9la proceeded with excellent positional selectivity. Likewise, ortho- and para-disubstituted arenes 8m and 8n underwent the site-selective meta-C-H alkylation with the ruthenium(II)-MPAA catalytic system. Subsequently, the robustness of the ruthenium(II) catalyst was probed with various unactivated tertiary alkyl bromides 2 under otherwise identical reaction conditions. Thus, 1-methylcyclohexyl bromide (2b) gave the C-H alkylated products 9ab-9mb. Sterically more congested tertiary alkyl bromides 2h, 2c, and


2d afforded the desired products 9 as well. Tertiary alkyl bromides 2 bearing functional groups, such as an arene, an ether, an alkene, or the chloro group, were well tolerated (9ai–9ag). Intriguingly, the *meta-tert*-alkylated product 9ag was not contaminated by the *ortho*-primary²⁵ alkylated arene, again demonstrating the useful chemo-selectivity. The versatile ruthenium(II)–MPAA catalyst was not restricted to the strongly coordinating pyridine derivatives. Indeed, the synthetically useful pyrazole and pyrimidine groups also served as the site-selectivity ensuring entities for the C–H *meta*-alkylation, affording the corresponding *meta*-alkylated products 10aa–10ba and 11ae–11ba, respectively.

Mechanistic Studies. In consideration of the unique catalytic activity of the ruthenium(II)–MPAA complexes, we became intrigued by studying their mode of action. To this end, we performed intermolecular competition experiments between differently substituted phenylpyridines 8,²⁶ which revealed electron-deficient arenes to be inherently more reactive than their electron-neutral or electron-rich counterparts (Scheme 5). This phenomenon renders a simple electrophilic substitution-type mechanism unlikely to be operative.










Interestingly, the relative reaction rates across these different classes of electrophiles were similar. Furthermore, the positional selectivity that was observed in single-component reactions with individual electrophiles was preserved in the competition experiments. Indeed, the primary alkyl bromide furnished the *ortho*-substituted product,^{25a} while the secondary and tertiary electrophiles delivered the *meta*-substitution pattern.

Subsequently, we conducted C–H functionalization with isotopically labeled compounds (Scheme 7). In the course of the *meta*-alkylation of arene $[D_s]$ -**8b**, a significant D/H exchange was observed, which was solely detected in the *ortho*-position of the product $[D_n]$ -**9ba** and the reisolated substrate $[D_n]$ -**8b** (Scheme 7a). This result provided strong

Scheme 7. Isotopic Labeling Studies




support for the C-H bond metalation step to proceed by an initial ortho-metalation in a reversible manner. We also performed the standard meta-C-H alkylation in the presence of D₂O (Scheme 7b). Here, a significant amount of deuterium incorporation in the *ortho*-positions of both product $[D_n]$ -9aa and the recovered starting material $[D_n]$ -8a was noted. To probe the mode of the meta-C-H cleavage and the C-C formation, substrate $[D_3]$ -8b was subjected to the optimized reaction conditions (Scheme 7c). Careful ¹H NMR spectroscopic analysis did not show any hydrogen incorporation in the *meta*-position, neither in the product $[D_2]$ -9ba nor in the recovered starting material $[D_3]$ -8b. These findings indicate the meta-C-H cleavage and C-C forming elementary steps likely to be irreversible in nature. It is interesting to note that the C-H alkylation with isotopically labeled alkyl bromide $[D_q]$ -2a resulted in a H/D exchange in the ortho-positions of both the product $[D_n]$ -9aa and the recovered starting material $[D_n]$ -8a (Scheme 7d). This experiment revealed key information on the dual role of the organic electrophile 2a, in that it not only served as the electrophilic alkylating reagent, but also as the proton source for the key elementary step of protodemetalation.


The kinetic isotope effect (KIE) of the *meta*-C–H cleavage was investigated by means of the initial rates for independent reactions of substrates **8b** and $[D_3]$ -**8b**, highlighting a KIE of $k_{\rm H}/k_{\rm D} \approx 1.6$ (Scheme 8). Intermolecular competition experiment between the substrates **8b** and $[D_3]$ -**8b** established a KIE of 1.4 as an average of two independent runs, which could be rationalized in terms of a kinetically relevant *meta*-C–H cleavage step.²⁷

Given the key importance of the cycloruthenated complexes as potential intermediates in the ruthenium(II)-catalyzed *meta*alkylation, we subsequently performed reactions with welldefined complexes **16a** and **17aa**. Notably, the chlororuthenacycle **16a** was not catalytically competent. However, the presence of cocatalytic amounts of the MPAA ligand Piv-Val-OH restored the catalytic ability, affording the *meta*alkylated **9aa** in an excellent yield (Scheme 9a).²⁶ These results clearly illustrate the importance of carboxylate assistance²⁸ for

Scheme 8. Kinetic Isotope Effect (KIE) Studies




Scheme 9. Reactions with Cyclometalated Ruthenium(II) Complexes



the ruthenium(II)-catalyzed C–H functionalization.²⁹ Moreover, the alkyl bromide *t*-BuBr (2a) was found to be indispensable for releasing the desired product 9aa from the cyclometalated ruthenium(II) complex 17aa (Scheme 9b). This observation illustrates the crucial relevance of the alkyl halides 2 for the proto-demetalation step.

Thereafter, we became interested in understanding the activation mode of the C–Br cleavage³⁰ as well as the nature of the meta-C-C forming step within the ruthenium(II)-catalyzed meta-alkylation with secondary and tertiary alkyl bromides. In this context, it is noteworthy that we^{12c} and subsequently Frost^{12d} had previously reported the detrimental effect exerted by the radical scavenger TEMPO. The independently prepared alkylpyridinium salt 18 was not a competent alkylating reagent (Scheme 10a). Moreover, the use of the alkene methylenecyclohexane (19a) did not afford the desired product 9ab, which rendered a reaction sequence comprised of β -elimination and a hydroarylation³¹ unlikely to be at play (Scheme 10b). Thereafter, the stereochemically well-defined cis- and trans-1bromo-4-phenylcyclohexanes $(14b)^{32}$ were utilized as electrophiles in two independent C-H functionalizations. Interestingly, both reactions delivered the same diastereomeric product mixture. This epimerization can be rationalized in terms of a



Scheme 10. Investigation on the meta-C-C Formation

homolytic C–Br cleavage. In good agreement with these observations, experiments with the radical clock (3-bromo-3-cyclopropyl)benzene (14c) furnished the *meta*-alkylated product 15ac with retention of the cyclopropane ring as the major product, along with 9% of the *meta*-homoallylated arene 15ac'. Thus, a radical rebound should feature a reaction rate being close to that previously observed for the ring opening of the cyclopropylmethylene radical of $7.0 \times 10^7 \text{ M}^{-1} \text{ s}^{-1.32}$ These findings are in agreement with the inhibition of the *meta*-alkylation by the radical scavenger TEMPO, as reported by us^{12c} and Frost.^{12d}

Finally, we performed a detailed kinetic analysis of the ruthenium(II)-catalyzed *meta*-C–H alkylation.²⁶ Hence, the reaction displayed the a priori expected first-order kinetics with respect to the arene **8b**. However, our studies revealed a second-order dependence on the concentration of the ruthenium catalyst (Figure 3). This unusual kinetic profile is suggestive of a second ruthenium complex being involved in or before the rate-determining step. Given the epimerization of the stereochemically well-defined substrates **14b** (vide supra), we thus propose a second ruthenium complex to facilitate the homolytic³⁴ C–Br cleavage within a homobimetallic³⁵ catalysis regime.³⁶

On the basis of our detailed mechanistic analysis, we propose the *meta*-C-H *tert*-alkylation to be initiated by the formation of the ruthenium(II)-MPAA complex 4 (Scheme 11). The catalytically active complex 4 is initially undergoing a reversible C-H ruthenation, thus leading to a H/D exchange in the *ortho*position of the arenes 1/8. Subsequently, a single-electron transfer-type activation of the alkyl halides 2 leads to intermediate 18. The formation of the radical intermediate hence rationalizes the previously observed racemization of enantiomerically enriched secondary alkyl halides as well as the inhibition by the radical scavenger TEMPO,^{12c} and provided a rational for the epimerization of the 1,4-disubstituted cyclo-





Figure 3. Double logarithmic plot of the initial rate versus the concentration of $[RuCl_2(p-cymene)]_2$ and the concentration of 2-phenylpyridine (**8b**).

Scheme 11. Plausible Catalytic Cycle



hexane derivatives as well as for the second-order dependence on the ruthenium concentration (Scheme 10c,d). Hydrogen atom abstraction delivers cyclometalated intermediate 17, which undergoes proto-demetalation with an additional equivalent of the alkyl halide 2. Thereby, the desired *meta*substituted product 3/9 is liberated and the catalytically active complex 4 regenerated.

CONCLUSION

In summary, we have reported on the first ruthenium(II)catalyzed meta-selective C-H functionalization with synthetically useful removable directing groups. Thus, N-acyl amino acids were found to be the key to success for the remote C-H tert-alkylation, which set the stage for the first ruthenium(II)catalyzed meta-functionalization of electron-rich aniline derivatives. Thereby, our removable auxiliary strategy provided a unique access to meta-substituted anilines, which complements traditional approaches. The power of the ruthenium(II)-MPAA-catalyzed remote C-H functionalization was reflected by efficient couplings with secondary and sterically congested tertiary alkyl halides. Detailed experimental mechanistic studies were conducted and provided strong support for an initial reversible cyclometalation by a ruthenium(II)-MPAA complex. Thereafter, a ruthenium-catalyzed homolytic C-Hal cleavage occurs, thus resulting in an unusual second-order dependence of the C-H functionalization rate on the ruthenium concentration. In more general terms, this report showcases, for the first time, the power of ruthenium-MPAA complexes for catalytic C-H functionalizations. Further, studies on the use of ruthenium-MPAA complexes in C-H functionalization are currently ongoing in our laboratories and will be reported in due course.

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b08435.

Experimental procedures, characterization data, and ${}^{1}H$ and ${}^{13}C$ NMR spectra for new compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

*lutz.ackermann@chemie.uni-goettingen.de

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Generous support by the European Research Council under the European Community's Seventh Framework Program (FP7 2007–2013)/ERC Grant agreement no. 307535, the CSC (fellowship to J.L.), the CaSuS Ph.D. program, the CAPES foundation, Ministry of Education of Brazil (fellowship to E.E.I.), the DFG (SPP 1807), and the Alexander von Humboldt Foundation (fellowship to S.D.S.) is gratefully acknowledged.

REFERENCES

 (1) Representative recent reviews on C-H activation: (a) Ye, B.; Cramer, N. Acc. Chem. Res. 2015, 48, 1308-1318. (b) Shin, K.; Kim, H.; Chang, S. Acc. Chem. Res. 2015, 48, 1040-1052. (c) Daugulis, O.; Roane, J.; Tran, L. D. Acc. Chem. Res. 2015, 48, 1053-1064.
 (d) Segawa, Y.; Maekawa, T.; Itami, K. Angew. Chem., Int. Ed. 2015, 54, 66-81. (e) Zhang, M.; Zhang, Y.; Jie, X.; Zhao, H.; Li, G.; Su, W. Org. Chem. Front. 2014, 1, 843-895. (f) Kuhl, N.; Schroeder, N.; Glorius, F. Adv. Synth. Catal. 2014, 356, 1443-1460. (g) Mesganaw, T.; Ellman, J. A. Org. Process Res. Dev. 2014, 18, 1097-1104. (h) Tani, S.; Uehara, T. N.; Yamaguchi, J.; Itami, K. Chem. Sci. 2014, 5, 123-135. (i) Girard, S. A.; Knauber, T.; Li, C.-J. Angew. Chem., Int. Ed. 2014, 53, 74-100. (j) Ackermann, L. J. Org. Chem. 2014, 79, 8948-8954. (k) Nakamura, E.; Hatakeyama, T.; Ito, S.; Ishizuka, K.; Ilies, L.; Nakamura, M. Org. React. 2014, 83, 1-209. (1) Gao, K.; Yoshikai, N. Acc. Chem. Res. 2014, 47, 1208-1219. (m) Rouquet, G.; Chatani, N. Angew. Chem., Int. Ed. 2013, 52, 11726-11743. (n) Wencel-Delord, J.; Glorius, F. Nat. Chem. 2013, 5, 369-375. (o) Schipper, D. J.; Fagnou, K. Chem. Mater. 2011, 23, 1594-1600. (p) Yeung, C. S.; Dong, V. M. Chem. Rev. 2011, 111, 1215-1292. (g) Nakao, Y. Chem. Rec. 2011, 11, 242-251. (r) Satoh, T.; Miura, M. Chem. - Eur. J. 2010, 16, 11212-11222. (s) Daugulis, O. Top. Curr. Chem. 2009, 292, 57-84. (t) Giri, R.; Shi, B.-F.; Engle, K. M.; Maugel, N.; Yu, J.-Q. Chem. Soc. Rev. 2009, 38, 3242-3272. (u) Ackermann, L.; Vicente, R.; Kapdi, A. Angew. Chem., Int. Ed. 2009, 48, 9792-9826. (v) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094-5115. (w) Bergman, R. G. Nature 2007, 446, 391-393 and references cited therein.

(2) Representative reviews: (a) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. Angew. Chem., Int. Ed. 2012, 51, 8960-9009. (b) Chen, D. Y. K.; Youn, S. W. Chem. - Eur. J. 2012, 18, 9452-9474. (c) Neufeldt, S. R; Sanford, M. S. Acc. Chem. Res. 2012, 45, 936-946. (d) McMurray, L.; O'Hara, F.; Gaunt, M. J. Chem. Soc. Rev. 2011, 40, 1885-1898.
(e) Gutekunst, W. R.; Baran, P. S. Chem. Soc. Rev. 2011, 40, 1976-1991. (f) Brückl, T.; Baxter, R. D.; Ishihara, Y.; Baran, P. S. Acc. Chem. Res. 2012, 45, 826-839.

(3) Selected reviews: (a) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624–655. (b) Satoh, T.; Miura, M. Top. Organomet. Chem. 2007, 24, 61–84. (c) Ackermann, L. Top. Organomet. Chem. 2007, 24, 35–60. (d) Omae, I. Coord. Chem. Rev. 2004, 248, 995–1023. (e) Kalyani, D.; Sanford, M. S. Top. Organomet. Chem. 2007, 24, 85–116. See also: (f) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. Angew. Chem., Int. Ed. 2012, 51, 10236–10254.

(4) Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147-1169.
(5) (a) Li, J.; De Sarkar, S.; Ackermann, L. Top. Organomet. Chem.
2015, DOI: 10.1007/3418_2015_130. (b) Yang, J. Org. Biomol. Chem.
2015, 13, 1930-1941. (c) Li, J.; Ackermann, L. Nat. Chem. 2015, 7, 686-687. (d) Julia-Hernandez, F.; Simonetti, M.; Larrosa, I. Angew. Chem., Int. Ed. 2013, 52, 11458-11460.

(6) Selected examples: (a) Cho, J. Y.; Tse, M. K.; Holmes, D.; Maleczka, R. E.; Smith, M. R. Science 2002, 295, 305–308.
(b) Ishiyama, T.; Takagi, J.; Ishida, K.; Miyaura, N.; Anastasi, N. R.; Hartwig, J. F. J. Am. Chem. Soc. 2002, 124, 390–391. (c) Phipps, R. J.; Gaunt, M. J. Science 2009, 323, 1593–1597. (d) Duong, H. A.; Gilligan, R. E.; Cooke, M. L.; Phipps, R. J.; Gaunt, M. J. Angew. Chem., Int. Ed. 2011, 50, 463–466. (e) Zhang, Y.-H.; Shi, B.-F.; Yu, J.-Q. J. Am. Chem. Soc. 2009, 131, 5072–5074. (f) Cheng, C.; Hartwig, J. F. Science 2014, 343, 853–857 and references cited therein.

(7) (a) Leow, D.; Li, G.; Mei, T. S.; Yu, J.-Q. Nature 2012, 486, 518–522. (b) Yang, G.; Lindovska, P.; Zhu, D.; Kim, J.; Wang, P.; Tang, R. Y.; Movassaghi, M.; Yu, J. Q. J. Am. Chem. Soc. 2014, 136, 10807–10813. (c) Tang, R. Y.; Li, G.; Yu, J.-Q. Nature 2014, 507, 215–220. (d) Lee, S.; Lee, H.; Tan, K. L. J. Am. Chem. Soc. 2013, 135, 18778–18781. (e) Bera, M.; Maji, A.; Sahoo, S. K.; Maiti, D. Angew. Chem., Int. Ed. 2015, 54, 8515–8519. See also: (f) Bresolw, R.; Zhang, X.; Huang, Y. J. Am. Chem. Soc. 1997, 119, 4535–4536.

(8) Wang, X.-C.; Gong, W.; Fang, L.-Z.; Zhu, R.-Y.; Li, S.; Engle, K. M.; Yu, J.-Q. *Nature* **2015**, *519*, 334–338.

(9) Dong, Z.; Wang, J.; Dong, G. J. Am. Chem. Soc. 2015, 137, 5887–5890.

(10) See also: Das, S.; Incarvito, C. D.; Crabtree, R. H.; Brudvig, G. W. Science **2006**, 312, 1941–1943.

(11) For recent reviews on ruthenium(II)-catalyzed C-H bond functionalizations, see: (a) Ackermann, L. Org. Process Res. Dev. 2015, 19, 260-269. (b) De Sarkar, S.; Liu, W.; Kozhushkov, S. I.;

Ackermann, L. Adv. Synth. Catal. 2014, 356, 1461–1479. (c) Thirunavukkarasu, V. S.; Kozhushkov, S. I.; Ackermann, L. Chem. Commun. 2014, 50, 29–39. (d) Li, B.; Dixneuf, P. H. Chem. Soc. Rev. 2013, 42, 5744–5767. (e) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. Chem. Rev. 2012, 112, 5879–5918. (f) Ackermann, L.; Vicente, R. Top. Curr. Chem. 2009, 292, 211–229 and references cited therein.

(12) (a) Ackermann, L.; Hofmann, N.; Vicente, R. Org. Lett. 2011, 13, 1875–1877. (b) Saidi, O.; Marafie, J.; Ledger, A. E.; Liu, P. M.; Mahon, M. F.; Kociok-Kohn, G.; Whittlesey, M. K.; Frost, C. G. J. Am. Chem. Soc. 2011, 133, 19298–19301. (c) Hofmann, N.; Ackermann, L. J. Am. Chem. Soc. 2013, 135, 5877–5884. During the preparation of our manuscript, we became aware of a very recent independent report by Frost and co-workers: (d) Paterson, A. J.; St John-Campbell, S.; Mahon, M. F.; Press, N. J.; Frost, C. G. Chem. Commun. 2015, 51, 12807–12810.

(13) (a) Wang, C.; Huang, Y. Synlett 2013, 24, 145–149.
(b) Rousseau, G.; Breit, B. Angew. Chem., Int. Ed. 2011, 50, 2450–2494.

(14) Rappoport, Z. The Chemistry of Anilines; Wiley: New York, 2007. (15) Song, W.; Ackermann, L. Chem. Commun. 2013, 49, 6638–6640.

(16) (a) Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. Br. J. Cancer 2006, 94, 1765–1769. (b) Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R. J. Clin. Oncol. 2009, 27, 6041–6051. (c) Owen, D. A.; Montana, J. G.; Keily, J. F.; Watson, R. J.; Baxter, A. D. U.S. Patent 6566384 B1, 2003. (d) Quintas-Cardama, A.; Kantarjian, H.; Cortes, J. Nat. Rev. Drug Discovery 2007, 6, 834–848.

(17) For preliminary reports, see: (a) Ackermann, L. BASF lecture, UC Berkeley, 11.03.2014. (b) Li, J. Doctoral Thesis, Georg-August-Universität Göttingen, 2015.

(18) Representative references: (a) Engle, K. M.; Yu, J.-Q. J. Org. Chem. 2013, 78, 8927–8955. (b) Wang, D.-H.; Engle, K. M.; Shi, B.-F.; Yu, J.-Q. Science 2010, 327, 315–319. (c) Engle, K. M.; Wang, D.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 14137–14151.

(19) Wu, X.; See, J. W. T.; Xu, K.; Hirao, H.; Roger, J.; Hierso, J.-C.; Zhou, J. Angew. Chem., Int. Ed. 2014, 53, 13573-13577.

(20) (a) Dudnik, A. S.; Fu, G. C. J. Am. Chem. Soc. 2012, 134, 10693–10697. (b) Zultanski, S. L.; Fu, G. C. J. Am. Chem. Soc. 2013, 135, 624–627.

(21) (a) Dersnah, D. F.; Baird, M. C. J. Organomet. Chem. **1977**, 127, C55–C58. (b) Shinoda, S.; Inoue, N.; Takita, K.; Saito, Y. Inorg. Chim. Acta **1982**, 65, L21–L23. (c) Severin, K.; Bergs, R.; Beck, W. Angew. Chem., Int. Ed. **1998**, 37, 1635–1654.

(22) Desai, L. V.; Stowers, K. J.; Sanford, M. S. J. Am. Chem. Soc. 2008, 130, 13285–13293.

(23) During the preparation of our manuscript, we became aware of a related independent report by Frost and co-workers; see ref 12d.

(24) (a) Alvarez-Builla, J.; Vaquero, J. J.; Barluenga, J. Modern Heterocyclic Chemistry; Wiley-VCH: Weinheim, 2011. (b) Mei, T.-S.;

Kou, L.; Ma, S.; Engle, K. M.; Yu, J.-Q. *Synthesis* **2012**, *44*, 1778–1791. (25) (a) Ackermann, L.; Novak, P.; Vicente, R.; Hofmann, N. Angew.

Chem., Int. Ed. **2009**, *48*, 6045–6048. (b) Ackermann, L. *Chem. Commun.* **2010**, *46*, 4866–4877.

(26) For detailed information, see the Supporting Information.

(27) Simmons, E. M.; Hartwig, J. F. Angew. Chem., Int. Ed. 2012, 51, 3066–3072.

(28) Ackermann, L. Chem. Rev. 2011, 111, 1315-1345.

(29) Ackermann, L. Acc. Chem. Res. 2014, 47, 281-295.

(30) A recent contribution: Miloserdov, F. M.; McKay, D.; Munoz, B. K.; Samouei, H.; MacGregor, S. A.; Grushin, V. V. *Angew. Chem., Int. Ed.* **2015**, *54*, 8466–8470 and references cited therein.

(31) For recent reviews on catalytic hydroarylation reactions, see: (a) Foley, N. A.; Lee, J. P.; Ke, Z.; Gunnoe, T. B.; Cundari, T. R. Acc. Chem. Res. **2009**, 42, 585–597. (b) Bandini, M.; Emer, E.; Tommasi, S.; Umani-Ronchi, A. Eur. J. Org. Chem. **2006**, 2006, 3527–3544. (c) Nevado, C.; Echavarren, A. M. Synthesis 2005, 2005, 167–182.
(d) Liu, C.; Bender, C. F.; Han, X.; Widenhoefer, R. A. Chem. Commun. 2007, 3607–3618. (e) Kakiuchi, F.; Chatani, N. Adv. Synth. Catal. 2003, 345, 1077–1101 and references cited therein.

(32) For the recent use of related alkyl iodides in palladium-catalyzed reactions, see: Zhang, S.-Y.; Li, Q.; He, G.; Nack, W. A.; Chen, G. J. Am. Chem. Soc. 2015, 137, 531–539.

(33) Bowry, V. W.; Lusztyk, J.; Ingold, K. U. J. Am. Chem. Soc. 1991, 113, 5687–5698.

(34) Kharasch, M.; Jensen, E.; Urry, W. Science 1945, 102, 128.

(35) Recent reviews: (a) Perez-Temprano, M. H.; Casares, J. A.; Espinet, P. Chem. - Eur. J. 2012, 18, 1864–1884. (b) Park, J.; Hong, S. Chem. Soc. Rev. 2012, 41, 6931–6943.

(36) For recent examples of ruthenium-catalyzed atom transfer radical additions, see: (a) Kiefer, G.; Ruiz, J.; Solari, E.; Hilt, G.; Severin, K. *Eur. J. Org. Chem.* **2012**, 77, 93–98. (b) Thommes, K.; Kiefer, G.; Scopelliti, R.; Severin, K. *Angew. Chem., Int. Ed.* **2009**, 48, 8115–8119. (c) Richel, A.; Delfosse, S.; Cremasco, C.; Delaude, L.; Demonceau, A.; Noels, A. F. *Tetrahedron Lett.* **2003**, 44, 6011–6015 and references cited therein.